HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk



Study Estimates Event-Free Survival with Combination SGLT2 and ACE/ARBs in People without Diabetes

November 23, 2022

Using data from a trio of trials, investigators provide insight into the potential benefits of combination therapy with SGLT2 inhibitors and RAAS inhibition on event-free survival among patients with chronic kidney disease without diabetes.

Cardiology Month in Review: July 2022

July 30, 2022

Our cardiology month in review spotlights the most popular content from the past month. The top content from July 2022 includes hormone therapy guidance from NAMS, a look at the potential for increased risk of kidney damage with a popular statin, and a recap of upcoming decisions and trials of interest in cardiometabolic from the second half of 2022.

Don't Miss a Beat: Understanding GFR Slope, with Brendon Neuen, MBBS, MSc

July 23, 2022

In the latest edition of Don’t Miss a Beat, Drs. Greene and Vaduganathan are joined by special guest Brendon Neuen, MBBS, MSc, of the George Institute of Global Health. A trialist currently contributing to the FIND-CKD trial, Neuen takes Vaduganathan and Greene on a deep dive into the use of GFR slope as an end point in clinical trials and as a tool in clinical practice.

Medicare Advantage Beneficiaries Less Likely to Receive GLP-1 RA and SGLT2 Inhibitor Prescriptions

July 14, 2022

A comparison of data from more than 340,000 Medicare beneficiaries with diabetes provides insight into the real-world differences in the management of these patients, including disparities in the prescription of GLP-1 RAs and SGLT2 inhibitors.

Increased Physical Activity Linked to Lower Cardiovascular Risk in Chronic Kidney Disease

July 13, 2022

An analysis of patients with CKD from the CRIC study demonstrates those with the highest levels of physical activity had reductions in risk of 36%, 29%, and 53% for atherosclerotic events, incident heart failure, and cardiovascular mortality, respectively, compared to those with the lowest levels.